Abstract
This chapter provides an over view of the book Advances in Antiviral Drug Design . |The book reviews the emerging new developments in the antiviral drug research field, thereby spanning the conceptual design and chemical synthesis of new antiviral compounds, their structure–activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use. Since the inception of the series on Advances in Antiviral Drug Design with Volume 1 in 1993, the antiviral chemotherapy field has continued to grow considerably. In addition to the established antiviral drugs (acyclovir, zidovudine, didanosine, zalcitabine, ribavirin, ganciclovir, and foscarnet), several new compounds have been approved (or may soon be approved): famciclovir and valaciclovir for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections; stavudine (D4T), saquinavir, and lamivudine (3TC) for the treatment of retrovirus ; and cidofovir for the treatment of human cytomegalovirus (HCMV) infections. The HIV protease has been considered as a paradigm for rational drug design. The enzyme is among the best understood in terms of both structure and action; and because of its crucial role in the maturation of HIV, it has been vigorously pursued as a target for anti-HIV chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
